Search results
Pfizer lifts profit view on cost cuts, demand for COVID products
Reuters· 1 day agoSales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal...
Pfizer Inc (PFE) Q1 2024 Earnings Call Transcript Highlights: Navigating Post-COVID Challenges ...
GuruFocus.com via Yahoo Finance· 18 hours agoCommercial Officer, Pfizer Inc.) The Part D redesign has several components that could impact Pfizer's business, including no cost-sharing for ...
Pfizer Jumps On 'Massive' First-Quarter Upside Thanks To Paxlovid Surprise
Investor's Business Daily· 1 day agoExcluding that, Paxlovid sales still topped expectations. Comirnaty, the Covid vaccine Pfizer...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 11 hours ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Pfizer Shares Jump After Beating Estimates
The Wall Street Journal· 1 day agoPfizer Chief Executive Albert Bourla said in an interview Wednesday he was encouraged but that the company's stock is undervalued.
Pfizer Inc (PFE) Q1 2024 Earnings: Adjusted EPS Surpasses Expectations Amidst Revenue Decline
GuruFocus.com via Yahoo Finance· 1 day agoStrategic and Operational Highlights Despite the challenges posed by declining COVID-19 product...
Pfizer lifts 2024 profit view on cost cuts, higher COVID vaccine demand
WHTC 1450 Holland· 2 days ago(Reuters) -Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 1 day agoCAR-T drugs are developed using a patient's own immune cells. Promisingly, Pfizer said in February...
CDC Found Evidence COVID-19 Vaccines Caused Deaths
WSAU Wausau· 1 day agoIn an exclusive report by the Epoch Times, U.S. Centers for Disease Control and Prevention (CDC) officials fou...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 4 hours agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter ...